News

Article October 8, 2019

New Bay Area Spin-Off Company to Develop Drugs for Multiple Sclerosis and Alzheimer’s Disease

Senior Investigator Katerina Akassoglou has fundamentally changed the way scientists think of neurological disorders. She made the seminal discovery that blood leaks are toxic to the brain by promoting inflammation and destroying neurons. Her research led the scientific community to reassess the complex relationship between the brain, immune, and vascular systems.

Business Development Institutional News Assay Development and Drug Discovery Core Multiple Sclerosis Neurological Disease Akassoglou Lab

Article August 15, 2018

A New Research Partnership to Find Treatments for Neurological Disorders

BioMotiv and Cure Network Dolby Acceleration Partners collaborate to advance the development of better treatments for brain disorders

Corporate Ventures and Translation Business Development News Release Epilepsy Neurological Disease Palop Lab

Article December 7, 2017

Gladstone Institutes Announces Research Collaboration with Lilly

Study will use innovative technology to focus on neurodegenerative diseases

Business Development News Release Finkbeiner Lab

Article December 21, 2011

Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s Disease

SAN FRANCISCO and PRINCETON, NJ—December 22, 2011—Bristol-Myers Squibb Company (NYSE:BMY) and the Gladstone Institutestoday announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.

Business Development